A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1
150
about 4.7 years
18+
19 sites in AR, CA, CO +10
About this study
This trial is testing a treatment called NKT3964 in adults with advanced or metastatic solid tumors. The goal is to see if this treatment is safe, how well it works, and what dose might be best.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take NKT3964
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants with Dose Limiting Toxicity (DLT) events, Objective Response Rate (ORR)
Secondary: Apparent clearance (CL/F) of NKT3964, Disease control rate, Duration of Response (DOR), Half-life (t1/2) of NKT3964, Maximum observed plasma concentration (Cmax) of NKT3964 with and without a high-fat and/or low-fat meal, Number of Participants with Adverse Events, Overall Survival (OS), Progression-free survival (PFS)
Oncology